By Colin Kellaher
Lexeo Therapeutics has hired Kyle Rasbach as chief financial officer of the clinical-stage genetic-medicine company.
Lexeo on Thursday said Rasbach, 44 years old, most recently served as chief business officer at Zentalis Pharmaceuticals.
The New York company said Rasbach will receive an initial annual base salary of $480,000 and a discretionary annual bonus with a target of up to 40% of his annualized salary for the preceding calendar year.
R. Nolan Townsend, Lexeo's chief executive, had been serving as the company's principal financial officer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 19, 2024 07:18 ET (12:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.